ABCB1 and prostate carcinoma: In turn, Lombard et al. demonstrated that upregulated ABCB1 mediates cross-resistance between taxanes and olaparib in C4-2B prostate cancer cells, which can be overcome by decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide [11].